Nanordica Medical Raises €1.6M as Trial Shows Its Nanotech Dressing Heals Chronic Wounds 3x Faster Than Silver Ions

How the Premotiv Wound Dressing Works

Conventional antibacterial wound care often relies on silver-ion dressings that can inhibit bacteria but may also slow the healing process . Nanordica’s researchers discovered that combining copper with silver nanoparticles creates a synergistic effect: the formula inactivates bacteria up to eight times more effectively than existing silver-ion solutions while using significantly less silver .

The contact layer of the Premotiv dressing is made from natural silk nanofibers embedded with these copper and silver nanoparticles . This design serves a dual purpose:

• Antibacterial action: The nanoparticles provide broad-spectrum protection against bacteria, including drug-resistant strains, without antibiotics .
• Tissue regeneration: The silk nanofiber matrix physically supports wound closure and tissue healing .

This approach reduces the risk of antibiotic resistance—a growing global health concern—particularly for patients with chronic wounds such as diabetic foot ulcers, surgical wounds, and traumatic injuries .

Clinical Trial Evidence

The most compelling data for Premotiv comes from a randomized controlled pilot trial (RCT) conducted at the North Estonia Medical Centre with 30 diabetic foot ulcer patients. The study, published in the Journal of Wound Care in April 2026, compared Premotiv head-to-head against Aquacel Ag+ Extra, the current market-leading silver dressing .

The results were striking:

• By the end of the one-week active treatment phase, wounds treated with Premotiv showed a 43% reduction in area, compared to just 13% for the silver dressing .
• 86% of hard-to-heal patients demonstrated improved wound healing after only three dressing applications .
• The study concluded that Premotiv was safe and effective, showing consistently better results across nearly all efficacy and safety endpoints .

These findings are now being tested at a much larger scale. Nanordica has launched a double-blind, randomized pivotal trial (NCT06667752) targeting at least 170 participants, again comparing Premotiv directly against Aquacel Ag+ Extra . The trial enrolled over 100 patients during 2025 alone, and its results are expected to form the core of the company’s regulatory submissions to the EU and FDA .

Upcoming Milestones and Market Path

Nanordica has already secured critical building blocks for its regulatory pathway. In 2025, the company achieved ISO 13485:2016 certification for its Quality Management System and was granted its first European patent for the nanoparticle technology .

The next major steps are regulatory clearances:

• CE marking under the EU Medical Device Regulation (MDR) is the next planned regulatory milestone, which would allow sales across Europe .
• FDA 510(k) clearance is also in the pipeline for entry into the U.S. market .
• A multicenter clinical trial expansion in Spain is in preparation to broaden the evidence base .

The first commercial launch is targeted for the 2026–2027 window, funded by the most recent investment round .

With positive pilot data in hand, a large confirmatory trial underway, and a new funding round to fuel the final push to market, Nanordica Medical is moving closer to offering clinicians an antibiotic-free alternative for some of the hardest-to-heal wounds in medicine.